Abstract:Background: Schizophrenia is a debilitating psychiatric disorder with diverse cognitive impairments. Insulin-like growth factor binding protein 1 (IGFBP-1), a ubiquitous negative regulator of IGF signaling, crosses the blood-brain barrier after peripheral synthesis. Given the crucial role of IGF signaling in cognitive function, we reasoned that altered serum IGFBP-1 concentrations might be associated with cognitive impairments in schizophrenia. To test this hypothesis, we examined the relationship between serum IGFBP-1 levels and cognitive performance in both medicated and treatment-resistant schizophrenia (TRS) patients. Methods: Serum IGFBP-1 was measured in 31 TRS patients, 49 chronic medicated schizophrenia (CMS) patients, and 53 healthy controls. Clinical symptom severity was evaluated using the Positive and Negative Syndrome Scale (PANSS) and cognitive functions using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results: Both TRS and CMS patients exhibited cognitive deficits compared to healthy controls (p < 0.05). Serum IGFBP-1 concentration differed significantly among groups (F=36.805, p < 0.001) and post hoc tests demonstrated significantly higher concentrations in both schizophrenia groups compared to controls (p < 0.001). Further, serum IGFBP-1 concentration was higher in the TRS group than the CMS group (p = 0.048). Correlation analysis identified a significant relationship between serum IGFBP-1 and attention in the TRS group (r = 0.411, p = 0.021), immediate memory in the CMS group (r = -0.417, p = 0.003), and RBANS total score in the CMS group (r = -0.368, p = 0.009). Multiple regression analysis adjusting for confounding factors revealed that serum IGFBP-1 was independently associated with attention in TRS patients (p = 0.016, 95 %CI. 0.002-0.015) and immediate memory in CMS patients (p = 0.022, 95 %CI-0.012 to -0.001). Conclusions: Elevated serum IGFBP-1 concentration may serve as a predictive biomarker for distinct cognitive deficits in TRS and CMS patients. Further investigations are warranted.

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits.

Abnormal glucose metabolism is associated with clinical symptoms of adolescent-onset patients with first-episode drug-naive schizophrenia

Disorders of glucose metabolism in medication-free patients with schizophrenia

Metabolism of Glucose in First-Episode Drug-Naive Patients with Schizophrenia and Their First-Degree Relatives

Glucose metabolism, hippocampal subfields and cognition in first-episode and never-treated schizophrenia

Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia

The prevalence, risk factors and clinical correlates of diabetes mellitus in Chinese patients with schizophrenia

Sex differences in plasma lipid profiles, but not in glucose metabolism in patients with first-episode antipsychotics-naïve schizophrenia

The Glycometabolism Abnormality among Schizophrenia Patients

The Comparison of Glycometabolism Parameters and Lipid Profiles Between Drug-Naïve, First-Episode Schizophrenia Patients and Healthy Controls

Association between increased BMI and cognitive function in first-episode drug-naïve male schizophrenia

Analysis of the influencing factors for the cognitive deficits in schizophrenic patients with diabetes

Glucose Metabolism and Sex Hormones in Male Patients with Medication-naïve First-episode Schizophrenia: A Large-scale Cross-sectional Study

The Prevalence and Clinical-Demographic Correlates of Diabetes Mellitus in Chronic Schizophrenic Patients Receiving Clozapine.

The prevalence and clinical characteristics of diabetes mellitus in Chinese inpatients with chronic schizophrenia: a multicenter cross-sectional study

Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese

Clinical correlates and metabolic indicators of elevated fasting glucose in overweight/obese Chinese Han patients with first-episode and drug-naive major depressive disorder

Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives

The Association Between Serum Insulin-Like Growth Factor 1 and Cognitive Impairments in Patients with Schizophrenia

Cognitive Impairments in First-Episode Drug-Naive and Chronic Medicated Schizophrenia: MATRICS Consensus Cognitive Battery in a Chinese Han Population.

Elevated serum IGFBP-1 levels correlate with cognitive deficits in treatment-resistant and chronic medicated schizophrenia patients